A.R. Pinho, A. Fortuna, A. Falc(a)o, A.C. Santos, R. Sei(c)a, C. Estevens, F. Veiga, A.J. Ribeiro. Comparison of ELISA and HPLC-MS methods for the determination of exenatide in biological and biotechnology-based formulation matrices[J]. Journal of Pharmaceutical Analysis, 2019, 9(3): 143-155.
Citation:
A.R. Pinho, A. Fortuna, A. Falc(a)o, A.C. Santos, R. Sei(c)a, C. Estevens, F. Veiga, A.J. Ribeiro. Comparison of ELISA and HPLC-MS methods for the determination of exenatide in biological and biotechnology-based formulation matrices[J]. Journal of Pharmaceutical Analysis, 2019, 9(3): 143-155.
A.R. Pinho, A. Fortuna, A. Falc(a)o, A.C. Santos, R. Sei(c)a, C. Estevens, F. Veiga, A.J. Ribeiro. Comparison of ELISA and HPLC-MS methods for the determination of exenatide in biological and biotechnology-based formulation matrices[J]. Journal of Pharmaceutical Analysis, 2019, 9(3): 143-155.
Citation:
A.R. Pinho, A. Fortuna, A. Falc(a)o, A.C. Santos, R. Sei(c)a, C. Estevens, F. Veiga, A.J. Ribeiro. Comparison of ELISA and HPLC-MS methods for the determination of exenatide in biological and biotechnology-based formulation matrices[J]. Journal of Pharmaceutical Analysis, 2019, 9(3): 143-155.
Laboratory of Pharmaceutical Technology, Faculty of Pharmacy, University of Coimbra, Pòlo das Ciências da Saúde, Azinhaga de Santa Comba, 3000-548 Coimbra, Portugal
Laboratory of Pharmacology, Faculty of Pharmacy, University of Coimbra, Pòlo das Ciências da Saúde, Azinhaga de Santa Comba, 3000-548 Coimbra,Portugal
CNC - Centre for Neuroscience and Cell Biology, University of Coimbra, 3004-517 Coimbra, Portugal
REQUIMTE/LAQV, Group of Pharmaceutical Technology, Faculty of Pharmacy, University of Coimbra, Pòolo das Ciências da Saúde, Azinhaga de Santa Comba,3000-548 Coimbra, Portugal
Laboratory of Physiology, IBILI, Faculty of Medicine, University of Coimbra, Pòlo das Ciênicas da Saúde, Azinhaga de Sante Comba, 300-548 Coimbra,Portugal
Pharmaceutical Development, TECNIMEDE, S. A. Quinta da Cerca, Caixaria, 2565-187 Dois Portos, Portugal
I3S, Instituto de Investiga(ca)o e Inova(ca)o em Saúde, Group Genetics of Cognitive Dysfunction, IBMC - Instituto de Biologia Molecular e Celular, Rua do Campo Alegre 823, 4150-180 Porto, Portugal
The development of biotechnology-based active pharmaceutical ingredients, such as GLP-1 analogs, brought changes in type 2 diabetes treatment options. For better therapeutic efficiency, these active pharmaceutical ingredients require appropriate administration, without the development of adverse effects or toxicity. Therefore, it is required to develop several quantification methods for GLP-1 analogs products, in order to achieve the therapeutic goals, among which ELISA and HPLC arise. These methods are developed, optimized and validated in order to determine GLP-1 analogs, not only in final formu-lation of the active pharmaceutical ingredient, but also during preclinical and clinical trials assessment. This review highlights the role of ELISA and HPLC methods that have been used during the assessment for GLP-1 analogs, especially for exenatide.
DownLoad: